“ASSOCIATION BETWEEN PSORIASIS VULGARIS AND HYPERTENSION: A CROSS-SECTIONAL STUDY”
Main Article Content
Keywords
Psoriasis vulgaris; Hypertension; Psoriasis Area and Severity Index (PASI); Disease severity; Cardiovascular comorbidity; Tertiary care centre
Abstract
Psoriasis vulgaris is a common chronic inflammatory dermatosis increasingly recognised as a systemic disease associated with cardiovascular comorbidities, including hypertension.
Objective: To determine the prevalence of hypertension among patients with psoriasis vulgaris attending a tertiary care dermatology outpatient department.
Methods: A hospital-based cross-sectional study was conducted over one year (January 2024 to January 2025). A total of 330 adult patients with psoriasis vulgaris were enrolled. Blood pressure was measured using standard procedures, and hypertension was defined as systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg or current use of antihypertensive medications.
Results: Out of 330 patients, 102 (30.9%) were found to have hypertension. Higher prevalence was observed in patients aged ≥40 years, with longer disease duration and greater psoriasis severity.
Conclusion: Psoriasis vulgaris is associated with a high prevalence of hypertension, highlighting the importance of routine cardiovascular screening in dermatology practice.
References
2. Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. Lancet. 2021;397(10281):1301–1315.
3. Dogra S, Yadav S. Psoriasis in India: prevalence and pattern. Indian J Dermatol Venereol Leprol. 2010;76(6):595–601.
4. Samarasekera EJ, Neilson JM, Warren RB, Parnham J, Smith CH. Incidence of cardiovascular disease in individuals with psoriasis. J Invest Dermatol. 2013;133(10):2340–2346.
5. Mehta NN, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Cardiovascular mortality in severe psoriasis. Arch Dermatol. 2010;146(12):1383–1388.
6. Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM. Cardiovascular risk factors in psoriasis. J Am Acad Dermatol. 2006;55(5):829–835.
7. Sommer DM, Jenisch S, Suchan M, Christophers E, Weichenthal M. Metabolic syndrome in psoriasis. Arch Dermatol Res. 2006;298(7):321–328.
8. Qureshi AA, Choi HK, Setty AR, Curhan GC. Psoriasis and hypertension risk. Arch Dermatol. 2009;145(4):379–382.
9. Cohen AD, Weitzman D, Dreiher J. Psoriasis and hypertension. Acta Derm Venereol. 2010;90(1):23–26.
10. Armstrong AW, Harskamp CT, Dhillon JS, Armstrong EJ. Psoriasis and hypertension: meta-analysis. J Hypertens. 2013;31(3):433–442.
11. Fredriksson T, Pettersson U. Severe psoriasis—oral therapy with a new retinoid. Dermatologica. 1978;157(4):238–244.
12. Zhang Y, Jiang X, Chen Y, Huang Y, Fang W. Hypertension in psoriasis: meta-analysis. J Invest Dermatol. 2025;145(2):456–465.
13. Takeshita J, Wang S, Shin DB, et al. Psoriasis severity and hypertension control. JAMA Dermatol. 2015;151(2):161–169.
14. World Health Organization. Global report on psoriasis. Geneva: WHO; 2016.
15. Madanagobalane S, Anandan S. Metabolic syndrome in South Indian psoriasis patients. J Assoc Physicians India. 2012;60:18–22.
16. Singh S, Young P, Armstrong AW. Psoriasis and metabolic syndrome. G Ital Dermatol Venereol. 2016;151(6):663–677.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Dr. Rahul Purushottam Kote
Associate Professor, Department of Dermatology, SMBT Institute Of Medical Sciences And Research Centre, Dhamangoan. Nashik
Dr Amol Narayan Rajdeo
Associate Professor, Department of Dermatology, SMBT Institute Of Medical Sciences And Research Centre, Dhamangoan. Nashik
Dr. Rahul Sugandhrao Deshmukh
Assistant Professor, Department of Dermatology, Institute Of Medical Sciences And Research Centre, Dhamangoan. Nashik
